616
Views
168
CrossRef citations to date
0
Altmetric
Review

Vascular risk factors, cognitve decline, and dementia

&
Pages 363-381 | Published online: 11 Apr 2008

Abstract

Dementia is one of the most important neurological disorders in the elderly. Aging is associated with a large increase in the prevalence and incidence of degenerative (Alzheimer’s disease) and vascular dementia, leading to a devastating loss of autonomy. In view of the increasing longevity of populations worldwide, prevention of dementia has turned into a major public health challenge. In the past decade, several vascular risk factors have been found to be associated with vascular dementia but also Alzheimer’s disease. Some longitudinal studies, have found significant associations between hypertension, diabetus mellitus, and metabolic syndrome, assessed at middle age, and dementia. Studies assessing the link between hypercholesterolemia, atrial fibrillation, smoking, and dementia have given more conflicting results. Furthermore, some studies have highlighted the possible protective effect of antihypertensive therapy on cognition and some trials are evaluating the effects of statins and treatments for insulin resistance. Vascular risk factors and their treatments are a promising avenue of research for prevention of dementia, and further long-term, placebo-controlled, randomized studies, need to be performed.

Introduction

Dementia is one of the most important neurological disorders in the elderly. As life expectancy increases, the worldwide number of demented patients is projected to grow from 24.3 million in 2001 to 81.1 million in 2040 (CitationFerri et al 2005). In occidental countries, the most common forms of dementia are Alzheimer’s disease (AD) and vascular dementia (Vad), with respective frequencies of 70% and 15% among all dementias (CitationWhitehouse et al 1997). AD is the most common primary neurodegenerative disorder in the elderly. Its neuropathological hallmarks are intraneuronal protein clusters of hyperphosphorylated tau protein (neurofibrillary tangles) and extracellular Aβ protein aggregation. This aggregation is the result of an abnormal amyloid precursor protein (APP) cleavage by β- and γ-secretases and initiates a pathogenic, self-perpetuating cascade ultimately leading to neuronal loss and dementia (CitationCummings et al 2004). In this context, the prevention of cognitive disorders represents a major challenge in the coming years. The identification of the risk factors for these debilitating conditions must be a priority in order to define the best approach for early prevention.

In the past decade, several vascular risk factors have been found to be associated with not only Vad but also, surprisingly, AD. We propose a review of these epidemiological associations and their underlying pathophysiological mechanisms (apolipoprotein E, hypertension, diabetus mellitus, obesity and metabolic syndrome, hypercholesterolemia, atrial fibrillation, smoking, atherosclerosis). Studies included in this non-systematic review were identified by searches of Medline and were restricted to papers published in English. The search terms were: apolipoprotein E, hypertension, diabetus mellitus, obesity and metabolic syndrome, hypercholesterolemia, atrial fibrillation, smoking, atherosclerosis, heart failure, coronary heart disease AND Alzheimer’s disease OR dementia OR cognitive decline. Some relevant review articles were taken into account and their bibliographies were screened. Some original case-control, population-based, and intervention studies were included.

Apolipoprotein E genotype and cognitive decline

Numerous genes related to vascular disease have been shown to increase susceptibility for sporadic AD (CitationPanza et al 2004). Among them, apolipoprotein E (Apo E), which occurs in three common alleles (ε2, ε3, ε4), is the best documented. The Apo E protein is one of the major constituents in very low-density lipoproteins and plays a key role in the transport of cholesterol among various cells of the body. The ApoE ε4 allele is known to be associated with coronary artery disease and the development of atherosclerosis (CitationDavignon et al 1988; CitationEichner et al 2002). This association is presumably related to the higher levels of total cholesterol, low density lipoprotein cholesterol (LDL-C) and apolipoprotein B in subjects homozygous for the APoE ε4 genotype than in those carrying ε2 or ε3.

Epidemiological studies have found an association between the ε4 allele of ApoE and familial and sporadic late-onset AD (CitationSaunders et al 1993). Furthermore, ApoE ε4 is associated with a younger onset of AD in a dose-dependent manner (CitationBlacker et al 1997). Similarly, the Apo E genotype seems to predict the rate of cognitive decline in AD, in a dose-dependent relationship with the ApoE ε4 allele (CitationMartins et al 2005). Mechanisms which could explain the effects of ApoE on the brain of AD subjects are still unclear. They include isoform specific toxicity, ApoE ε4- mediated amyloid aggregation, ApoE ε4- mediated tau hyperphosphorylation, and isoform-driven ApoE concentration changes (CitationPanza et al 2006). ApoE could also modulate the distribution and metabolism of cholesterol in neuronal membranes in an isoform-dependent manner, which may be relevant to Apo E-related pathogenic effects and the development of AD (CitationYanasigawa 2002).

Hypertension and cognitive decline

The relationship between cognitive function and blood pressure has been the subject of numerous conflicts in the literature. The results of epidemiological studies vary with the methodology used. Cross-sectional studies have found not only positive (CitationStarr et al 1993; CitationSeux et al 1998) but also negative (CitationFarmer et al 1987; CitationScherr et al 1991) correlations between arterial hypertension and cognitive impairment. Longitudinal studies are more informative since they evaluate the effect of “chronic” hypertension on cognitive function. Most of them indicate a positive relationship between the presence of hypertension in midlife and the onset of cognitive decline 15–20 years later (). CitationSkoog et al (1996) have demonstrated that blood pressure values measured at 70 years old were higher in patients developing dementia between the ages of 79 and 85 years than in non-demented subjects. Conversely, in the years preceding the onset of dementia, their blood pressures became identical to or less than those of patients who did not develop dementia. Others studies have observed a similar decrease in blood pressure in patients with AD (CitationHanon et al 2005b; CitationVerghese et al 2003). CitationGuo et al (1996) reported that blood pressure was lower in individuals over 75 years old with AD compared to patients without dementia and that blood pressure levels decreased with increasing severity of dementia. The reason for the decrease in blood pressure in patients with dementia has not been fully clarified. Whether the blood pressure decline is a cause or an effect of AD is not known. Physical inactivity in those afflicted by advancing mental deterioration as well as body mass and metabolic changes may all play a role. Finally, a recent study including 700 patients with AD found a significant association between hypertension and increased cognitive decline over a 6-month period (odds ratio [OR] = 1.6 [95% CI = 1.0–2.7]) (CitationBellew et al 2004).

Table 1 Blood pressure (BP) and cognitive decline or dementia. Longitudinal studies

To conclude, the connection between blood pressure and cognitive functions is more complex than a simple linear relationship. Chronic hypertension predisposes to cognitive decline and the development of dementia, but a decrease in blood pressure can be observed in the late interval preceding the onset of dementia and afterward.

The role of lowering blood pressure for the prevention of cognitive decline and dementia is of central importance and has been assessed in both non-randomized studies and several randomized clinical trials.

Non-randomized studies have yielded divergent results concerning the effect of antihypertensive drugs on cognitive functions. A negative effect of antihypertensive drugs on cognitive functions was suspected (CitationHeckbert et al 1997; CitationMaxwell et al 1999). Instead, CitationGuo et al (1999) have shown a significant reduction in the risk of dementia as a result of antihypertensive treatment (relative risk [RR] of 0.7, 95% CI = 0.6–1.0). In the HOPE study (CitationStarr et al 1996), cognitive improvement was seen in subjects treated with diuretics or angiotensin converting enzyme inhibitors who had the greatest drop in blood pressure. Moreover, in the EVA cohort (CitationTzourio et al 1999), the risk of cognitive decline after 4 years of follow up was significantly lower in hypertensive subjects who received treatment compared to untreated hypertensive subjects (1.9 [95% CI = 0.8–4.4] versus 4.3 [95% CI = 2.1–8.8]). Similarly, a study of 1617 elderly African-American subjects followed for 5 years, indicated a significant 38% decrease in cognitive decline in treated hypertensive subjects compared with untreated subjects (OR = 0.62, 95% CI = 0.45–0.84) (CitationMurray et al 2002). Moreover, a recent study found that in a sample of 1241 elderly patients, the odds ratio for AD was 0.58 (95% CI = 0.42–0.81) in treated compared with untreated hypertensive patients (CitationHanon et al 2006). Lastly, the recent Cache County Study performed in 3,308 people (Mean age 75 years), followed up 3 years, indicated a significant reduction of the risk of AD from 36% (OR = 0.64, 95% CI = 0.41–0.98) (CitationKhatchaturian et al 2006). Moreover, data from the Honolulu Asia Aging Study showed that the duration of antihypertensive therapy also mattered: For each additional year of treatment, there was a reduction in the risk of dementia incidence (hazard ratio [HR] = 0.94, 95% CI = 0.89–0.99) (CitationPeila et al 2006)

By definition, however, observational studies are subject to bias, and randomized, placebo-controlled studies are necessary to investigate the relationship between antihypertensive treatment and cognitive functions.

Six large randomized placebo-controlled trials have evaluated the effects of antihypertensive drugs on cognitive functions. Their results are summarized in .

Table 2 Effect of antihypertensive drugs on cognitive decline or dementia in randomised, placebo - controlled studies

In the MRC project (CitationPrince et al 1996), a subgroup of 2584 elderly subjects followed for 54 months showed no difference in neuropsychometric tests in the treated group (Diuretic or β-blocker) compared to the placebo group. In this study, however, the evaluation of cognitive functions was insufficiently detailed and the 54-month follow up period may have been too short to detect a difference between the 2 groups.

In the SHEP study (CitationSHEP Cooperative research group 1991) the incidence of dementia was not statistically different in the group receiving active treatment with diuretic and/or β-blocker (1.6%) compared to the group receiving placebo (1.9%), after 5 years of follow-up, although it was slightly lower in the first group. In this study, however, differential dropout biased the cognitive evaluations and may have obscured the assessment of a preventive effect of treatment on cognitive decline (CitationDi Bari et al 2001).

On the other hand, the Vascular Dementia project included in the SYST-EUR study (CitationForette et al 1998) demonstrated for the first time a reduction in the incidence of dementia with antihypertensive treatment. The study was conducted over 2 years in patients with isolated systolic hypertension who were at least 60 years old, randomized to receive the active treatment (n = 1238) or placebo (n = 1180). The active treatment was a calcium channel blocker (nitrendipine), possibly combined with an ACE-inhibitor (enalapril) and/or a diuretic (hydrochlorothiazide). The incidence of dementia was reduced by 50% in the active treatment group compared with the placebo group (p = 0.05). These findings were based on only 32 incident cases. Nevertheless, the incidence of AD was reduced as well as the incidence of vascular or mixed dementia.

After the double-blind, placebo-controlled period, all patients withdrawing from double-blind were invited to continue or start the study antihypertensive treatment for a median period of 2 years (SYST-EUR 2) (CitationForette et al 2002). The incidence of dementia was updated in patients treated since randomisation (4 years) compared to patients who were actively treated only since the end of the double blind period (2 years). After 4 years, there was still a significant difference in blood pressure between the two groups. Compared with the controls, long-term antihypertensive therapy reduced the incidence of dementia by 55% from 7.4 to 3.3 cases per 1000 patient-years (p < 0.001). Both types of dementia (AD and Vad or mixed dementia) were reduced.

Dementia and cognitive decline were secondary outcomes of the placebo-controlled trial PROGRESS (CitationTzourio et al 2003). Treatment consisted of perindopril possibly combined with indapamide or a matching placebo. After 4 years of follow up, active treatment significantly reduced the risk of cognitive decline by 19% in the whole population. The risk of dementia was reduced by 12% (95% CI = −8% to 28%) in the active treatment-group and significantly by 34% in patients with recurrent stroke. Similarly, in patients receiving the combination therapy, the risk of dementia was significantly reduced by 23% (95% CI = 0%–41%).

Data from the HOPE study (CitationBosch et al 2002) of 9297 patients with vascular disease or diabetes and an additional vascular risk factor followed over 4.5 years, have demonstrated a significant 41% reduction in cognitive decline associated with stroke in the ACE inhibitor group (ramipril 2.5–10 mg) compared to placebo.

Finally, the SCOPE study (CitationLithell et al 2003) has evaluated the effect of an angiotensin receptor blocker ± diuretic on the cognitive function of 4964 elderly (70–89 years) hypertensive patients without dementia. After 3.7 years of follow up, no significant difference between the two groups was found for cognitive function and dementia. However, this lack of benefit could probably be attributed to the fact that most patients in the placebo group were treated with other antihypertensive drugs for ethical reasons. Moreover, the cognitive evaluation was based solely on the MMSE (Mini Mental State Examination) which lacks the sensitivity to detect a slight cognitive decline in subjects without dementia. Lastly, a recent analysis of SCOPE (CitationSkoog et al 2005) has indicated a significant reduction of cognitive decline in the subgroup of subjects with already low cognitive function at baseline (MMSE score between 24 and 28), whereas no benefit was observed in people with normal cognitive function.

Some recent meta-analyses concerning these randomized, placebo-controlled studies were able to give a more complete picture of the effects of antihypertensive treatments on cognition. Some of them have supported a benefit of antihypertensive treatments for preventing dementia (CitationFeigin et al 2005; CitationBirkenhager and Staessen 2006) or cognitive disorders (CitationBirns et al 2006).

Alternatively, the Cochrane review concluded that blood pressure reduction resulted in an 11% reduction in the relative risk of dementia in patients with no prior cerebrovascular disease, but this effect was not statistically significant (p = 0.38). Nevertheless, this review takes into account only 3 studies (SCOPE, SHEP, and SYST-EUR) which could minimize the effects of antihypertensive therapy (McGuiness et al 2006).

There are multiple underlying pathophysiological mechanisms that could give an explanation for the association between hypertension and dementia.

Data from histopathological studies indicate a major overlap between vascular lesions and AD (CitationArregui et al 1982; CitationVictoroff et al 1995; CitationSnowdon et al 1997). By promoting arteriosclerosis and lipohyalinosis of the small vessels, hypertension might be the origin of stroke and/or chronic hypoperfusion of the white matter, thus contributing to the early expression of a still subclinical AD. It has been shown that patients with high midlife systolic blood pressure (SBP) experience cognitive dysfunctions as well as increased volume of white matter hyperintensities in late life (CitationSwan et al 1998a,Citationb). A significant interaction between hypertension, ApoE ε4 allele and white matter lesions has been found (Citationde Leeuw et al 2004). It is also pointed out that the progression of the white matter lesions is highly correlated with cognitive decline. Furthermore, longitudinal studies found an increased risk of AD in people with periventricular white matter lesions (CitationPrinds et al 2004). In this way, a very recent study found that white matter hyperintensities on magnetic resonance imaging scan, were significantly associated with cognitive decline in MCI patients (mean follow-up = 3.8 ± 1.6 years) (CitationDebette et al 2007). Moreover, antihypertensive therapy has been showed to reduce white matter lesions progression in a longitudinal study including patients with a history of stroke (Dufouil et al 2005a). In this way, such presence of cerebral white matter lesions could be an indication for early neuroprotection. Microcirculation disorders and endothelial dysfunctions are also given as explanations for the cognitive impairment seen in hypertensive subjects. Hypertension is associated with degenerative changes of intracerebral capillaries and arterioles and ADis associated with lesions in the cerebral microvasculature (Perlmutter et al 1991). These vessel changes may compromise the function of the blood-brain barrier, leading to an increased vascular permeability and protein extravasation into the brain parenchyma, resulting in beta-amyloid accumulation (CitationHardy et al 1986). Likewise, hypertension and beta amyloid act on endothelial cells to produce an excess of free radicals suggesting that oxidative stress is involved in the mechanisms of both vascular disorders and AD. Finally, periods of hypotension, hypoperfusion and hypoxia, observed in hypertensive subjects, might contribute to cognitive deficits in AD patients via reduced cerebral perfusion causing ischemic neuronal lesions in vulnerable areas of the brain.

In summary, hypertension may impair cognitive functions and is related to the occurrence of not only vascular dementia but also AD. Randomized, placebo-controlled trials have demonstrated that blood pressure-reducing agents decrease the incidence of dementia in stroke patients (PROGRESS, HOPE) and in elderly patients with isolated systolic hypertension (SYST-EUR), but this was not found in SCOPE and SHEP.

In this context, the incidence of dementia should be a major outcome measure of future trials comparing different antihypertensive drugs.

Diabetus mellitus and cognitive decline

Type 2 diabetus mellitus (DM) is a common disease in the elderly affecting more than 10% of the elderly population in the US, and its prevalence increases with age (CitationHarris 1998).

A possible relationship between cognitive decline and diabetes has been suggested since the discovery of insulin (CitationMiles and Root 1922). A review of 33 longitudinal studies found that, in patients with type 1 diabetus mellitus, cognitive dysfunction was characterized by a slowing of mental speed and diminished mental flexibility, whereas learning and memory were spared (CitationBrands et al 2005).

Several longitudinal studies have shown a relationship between type 2 DM and accelerated cognitive decline (CitationAllen et al 2004). The results of the Atherosclerosis Risk In Communities study (ARIC) were of particular interest because of an adjustment used for confounding cardiovascular factors (CitationKnopman et al 2001). In this study of 10,963 middle aged people followed over 6 years, there was a significant association between type 2 DM and decline in sustained attention, psychomotor speed and logical reasoning as well as in verbal learning and recent memory. Moreover, in the same cohort, insulin resistance appeared to be a midlife risk factor for cognitive decline and dementia (CitationYoung et al 2006).

A review by CitationAllen et al (2004) put forward several limitations of these large longitudinal studies: Their vulnerability to survivor bias, the importance of confounding factors, their failure to record the duration of DM and the difficulty in choosing and conducting appropriate psychometric tests. More recently, a longitudinal study (CitationLuschinger et al 2007) including 918 participants (mean age = 75.9 years ± 6), with a mean follow-up of 6.1 ± 3.2 years per person, disclosed that DM was related to a higher risk of memory impairment (HR = 1.5; 95% CI = 1.0–2.2; p = 0.02 after adjusting for vascular risk factors). Globally, people with type 2 DM were at increased risk for developing cognitive impairment in comparison with the general population (CitationAllen et al 2004).

Although type 2 DM is a well-established risk factor for stroke (CitationStegmayer and Asplund 1995), conflicting results have been reported about its association with dementia, especially AD. Cross sectional studies have suggested an association between type 2 DM and dementia (CitationJanson et al 2004), but only longitudinal population-based studies can robustly asses the risk of developing dementia ascribable to DM.

Several studies have been designed with this aim and most of them have been included in a review by Biessels et al (CitationBiessels et al 2006).

Four studies () assessed the relationship between DM in midlife and dementia later in life. The Honolulu Asian Study initially failed to find a positive association between DM and Alzheimer Disease (CitationCurb et al 1999). Subsequent follow-up surveys in the same cohort disclosed a different result (CitationPeila et al 2002) which was consistent with neuropathological data: DM was associated with an increased risk for total dementia, AD, and VaD. This result was confirmed by the Japanese Adult Health Study (CitationYamada et al 2003). Similarly, 2 other long-term follow-up studies highlighted the link between DM and dementia (CitationSchnaider Beeri et al 2004; CitationWhitmer et al 2005). Nevertheless, these types of studies are particularly sensitive to survivor bias.

Table 3 Risk of incident dementia in patients with Diabetus mellitus in longitudinal studies

Studies in which DM is assessed late in life show a fairly consistent association between DM and dementia () (CitationOtt et al 1999; CitationLuchsinger et al 2001; CitationHassing et al 2002; CitationMacKnight et al 2002; CitationArvanitakis et al 2004; CitationXu et al 2004; CitationLuchsinger et al 2005).

The conclusion of Biessels et al was that, overall, the incidence of dementia was increased by 50%–100% in people with DM relative to those without diabetes. The increased risk included both AD and VaD (CitationBiessels et al 2006). Furthermore, a longitudinal study of 1177 subjects older than 75 years old, followed over 9 years, recently disclosed an association between borderline diabetes and dementia (1.67; 95% CI (1.04–2.67)) and AD (1.77; 95% CI (1.06–2.97)). This was independent of future development of DM, giving a great importance to the link between hyperglycemia and dementia (CitationXu et al 2007). Similarly, an association was found between glycosylated hemoglobin levels (HbA1c) and the risk of developing memory impairment or dementia in 1938 postmenopausal, osteoporotic women followed over 4 years. For every 1% increase in HbA1c, these women had a greater age-adjusted likelihood of developing mild cognitive impairment or dementia (OR = 1.40; 95% CI = 1.08–1.83) (CitationYaffe et al 2006).

One major modulatory factor in these studies was that DM was frequently associated with co-morbid conditions that are known to play a role in cognitive decline, such as hypertension and hypercholesterolemia. These co-morbid conditions could be important determinants of the increased risk of dementia in people with DM. Several studies provided results adjusted for cardiovascular disease. Two studies reported that adjusting for vascular risks factors did not change the results of univariate analysis (CitationMacKnight et al 2002; CitationPeila et al 2002) for all dementia subtypes. On the other hand, the Kungsholmen study found that systolic hypertension and diabetes combined to modify the relative risk of dementia when considering AD and VaD (CitationXu et al 2004).

Furthermore, ApoE genotype may be an important confounding factor. Two studies found out that Apo E ε4 genotype combined with DM doubled the relative risk of dementia compared with DM alone (CitationPeila et al 2002; CitationXu et al 2004). More recently, results of the Framingham Study pointed out that DM did not increase the risk of AD overall. After adjusting for the ApoE ε4 allele or elevated plasma homocysteine levels, however DM appeared as a risk factor for AD (CitationAkomolafe et al 2006). DM, then, was a strong independent risk factor for AD among people at a relatively lower initial risk for developing the disease. In conclusion, longitudinal studies now provide evidence that DM is a risk factor for cognitive decline and dementia (AD and VaD), but the pathophysiological mechanisms underlying this association are still unknown.

Brain autopsy studies may provide information about these underlying mechanisms. First, DM is associated with brain infarcts and pathological changes in the cerebral microvasculature including amyloid angiopathy (CitationPeila et al 2002). Furthermore, 216 autopsies from the Honolulu-Asia Aging Study showed that participants with type 2 DM and the ApoE ε4 allele had a higher number of neuritic plaques in the hippocampus and neurofibrillary tangles in the cortex and hippocampus (CitationPeila et al 2002).

Three main pathological mechanisms are proposed to explain the link between DM and dementia (CitationBiessels et al 2006; CitationQiu and Folstein 2006).

First, DM may lead to dementia through ischemic cerebrovascular disease. DM, especially in elderly people, often develops in a cluster of vascular risk factors which can constitute the metabolic syndrome, which is already known to be predictor of cerebrovascular disease (CitationKalmijn et al 2000; CitationYaffe et al 2004).

Second, hyperglycemia can have a direct toxic effect on neurons by causing oxidative stress and the accumulation of advanced glycation end products, a process which can directly affect brain tissue, and also lead to microvascular changes (CitationKumari et al 2000). Lastly, insulin and insulin-degrading enzymes could play an important role in amyloid metabolism (CitationQiu and Folstein 2006). Insulin resistance, at least in the early stages of DM, is associated with compensatory hyperinsulinemia and hyperinsulinemia even in the absence of diabetes and is strongly associated with AD (CitationLuschinger et al 2004). Insulin receptors are distributed with particular abundance in the hippocampus and cortex (CitationBondy and Cheng 2004). Insulin appears to stimulate amyloid β secretion and inhibits the extrascellular degradation of amyloid β (CitationGasparini and Xu 2003) by competing for insulin degrading enzyme which may be deficient (CitationQiu and Folstein 2006).

These data offer avenues to the prevention of dementia.

Considering longitudinal studies, strict control of DM seems to be an important goal in order to prevent subsequent dementia. However, the impact of intensive glucose-lowering treatments on the incidence of dementia is still unknown. The ADVANCE study will give some answers, as dementia is being considered as a secondary outcome (CitationRationale and design of the ADVANCE Study 2001).

In consideration of the underlying pathological mechanisms, researches are being conducted with treatments for insulin resistance such as Rosiglitazone® (CitationHsueh 2006) and gene therapy targeting insulin degrading enzyme (CitationQiu and Folstein 2006).

Adiposity, metabolic syndrome and cognitive decline

Obesity affects 25%–30% of adults in industrialised countries (CitationRennie and Jebb 2005). In the past, studies reported that a low body mass index (BMI) was a risk factor for dementia (CitationWhite et al 1996). However, these observations were based on cross-sectional studies, and with dementia, previously obese patients may lose up to 50% of their predementia body weight (CitationWang 2002). As rewieved by CitationGorospe and Dave (2007) and CitationGustafson (2006), epidemiological studies of increased BMI as a risk factor for dementia have shown conflicting results. Nevertheless, the studies with statistically significant results had larger sample sizes, longer follow-up periods and younger participants at baseline (CitationGorospe and Dave 2007). Thus, a 27-year longitudinal, population-based study of 10,276 subjects showed that people with a high BMI had a significant higher risk of dementia (HR = 1.74; 95% CI = 1.35–1.24) after adjusting with vascular comorbidities and socioeconomic status (CitationWhitmer et al 2005). Similarly, a study, that followed participants over 18 years, concluded that for every 1.0 increase in BMI at 70 years old, AD risk increased by 36% after adjusting with vascular confounding factors (CitationGustafson et al 2003). Two other well-designed and powerful studies found similar results (CitationKalmijn et al 2000; Rosengreen et al 2005). More recently a 36-year longitudinal study of a large cohort (n = 10,136) found that people who were obese at midlife (BMI >30) had a 3.10-fold increased risk of AD (HR = 3.10; 95% CI = 2.19–4.38) and a 5-fold increased in risk of Vad (HR = 5.01; 95% CI = 2.98–8.43), while those who were overweight (BMI > 25) had a 2-fold increased risk of AD and Vad (HR =2.09; 95% CI = 1.69–2.60 for Alzheimer disease and HR = 1.95; 95% CI = 1.29–2.96 for vascular dementia), independent of vascular comorbidities (CitationWhitmer 2007). All these results suggest that an increased BMI is likely to be an important risk factor for dementia, even though there are no published reports that take into account the role of ApoE ε4.

As for DM, excess adiposity could increase the risk of dementia by a vascular pathway (CitationGustafson 2006). Furthermore, adipose tissue secretes adipocytokines such as leptin which may be involved in neurodegenerative pathways (CitationBenoit et al 2004).

For now, then, an elevated BMI in middle age appears to be an important risk factor for dementia, and the maintenance of a normal weight could be a worthwhile intervention for the prevention of dementia (CitationGorospe and Dave 2007).

The metabolic syndrome is a cluster of cardiovascular risk factors including obesity. In most studies, it is defined using the National Education Program Third Adult Treatment Panel Guide (CitationExpert Panel 2001). It has been proven to be associated with an increased risk of developing cardiovascular disease (CitationExpert Panel 2001). It is also an independent risk factor for silent brain infarctions on magnetic resonance Imaging in middle age, healthy people (CitationKwon et al 2006).

Few studies have considered the components of the metabolic syndrome as a whole, whereas several individual components have been linked to risk of developing dementia and cognitive impairment. Furthermore, it is unclear whether the metabolic syndrome has a higher predictive value for the development of dementia than the sum of its individual components (CitationYaffe 2007).

Some transversal studies have shown a link between metabolic syndrome and cognitive impairment. A population-based study of 959 subjects (range 69 and 78 years old), found that metabolic syndrome was significantly associated with AD (OR = 2.46; 95% CI =1.27–4.78) (CitationVanhanen et al 2006). In addition, a cross-sectional study of the 1183 participants of the Longitudinal Aging Study Amsterdam showed that metabolic syndrome was associated to poorer cognitive functioning (CitationDik et al 2007). Lastly, a very recent case control study, showed that the metabolic syndrome was associated with AD (OR = 3.2, 95% CI = 1.2–8.4, p = 0.02) (CitationRazay et al 2007). This association was strengthened when the hypertension component was excluded.

A few studies with a longitudinal design have been conducted. First, in the Honolulu-Asia Aging study, the long term association between clustered metabolic cardiovascular risk factors in the middle age and the risk of dementia in old age was assessed. Z scores were calculated for 7 cardiovascular risk factors. The z-score sum was higher in subjects with dementia than in subjects without dementia (0.74 versus −0.06 respectively; p = 0.008). Per SD increase in the z-score sum, the risk of dementia was increased by 5% (RR = 1.05, 95% CI = 1.02–1.09). Considering the subtypes of dementia, significance was maintained only for vascular dementia (RR = 1.11, 95% CI = 1.05–1.18) (CitationKalmijn et al 2000). Furthermore, the Health Aging and Body Composition study assessed the cognitive abilities of 2,949 elderly subjects at baseline, 3 and 5 years by the Modified MMSE, and found that metabolic syndrome was associated with a greater likelihood of cognitive decline (OR = 1.21; 95% CI = 1.03–1.43) (CitationYaffe et al 2004). Similarly, the Sacramento Area Latino Study of Aging enrolled 1624 elderly Latinos subjects, who were cognitively evaluated yearly over three years by the Modified MMSE and the Delayed Word-List recall from the Spanish – English verbal learning test. Subjects with metabolic syndrome scored lower than those without metabolic syndrome on the Modified MMSE (p = 0.04), but the difference between the two groups on the Delayed Word – List recall was no longer significant (p = 0.18) (CitationYaffe et al 2007). These two last studies also found that the composite measure of metabolic syndrome was a greater risk for cognitive decline than its individual components.

Thus, metabolic syndrome seems to be a risk factor (CitationYaffe et al 2007) for cognitive decline, even though further long term prospective studies have to be conducted.

Mechanisms linking metabolic syndrome to cognition remain speculative (CitationYaffe et al 2007). An association between metabolic syndrome and cognitive decline could be explained by vascular disease. As previously studied in diabetus mellitus, insulin resistance seems to play a key role. This association could also be, a least partly, mediated by inflammation (CitationYaffe et al 2007). Lastly, central adiposity is a core feature of metabolic syndrome, so adipocytokines could also play a role (CitationBenoit et al 2004).

Cholesterol, statins, and cognitive decline

Several epidemiological studies have assessed the link between cholesterol levels and dementia, especially AD (CitationPanza et al 2006). Cross-sectional studies provided very conflicting results. A Finnish study of 980 people between 69 and 78 years old, found an association between low serum total cholesterol (TC) and AD, independent of ApoE genotype (OR = 0.69; 95% CI = 0.52–0.92, p = 0.011) (CitationKuusisto et al 1997). Another cross-sectional study of 1449 elderly subjects showed that decreased TC had an inverse association with the incidence of AD, independent of ApoE genotype (RR =1.6; 95% CI = 1.0–2.7) (CitationRomas et al 1999). The study of Evans et al found that high TC was associated with AD only in the group which lacked an ApoE 4 allele (OR = 1.018; p = 0.027) (CitationEvans et al 2000). Lastly, the three City Study, a population-based cohort of 9,294 subjects selected from electoral rolls, showed that higher TC (>6.20 mmol/L) was associated with increased odds of dementia (p = 0.07) but not AD (Dufouil et al 2005b).

Several more poverfull longitudinal studies have assessed the increased risk of dementia ascribable to high cholesterol levels. Their results are summarized in the .

Table 4 Association between cholesterol level and dementiain longitudinal studies

Two studies showed an epidemiologic link between high cholesterol level and Vad (CitationMoroney et al 1999; CitationReitz et al 2004). Nevertheless, the results of studies which have investigated the relationship between cholesterol levels and risk of AD or any dementia are conflicting (). Globally, when cholesterol level was assessed in the middle age, a positive association with AD was found (CitationNotolka et al 1998; CitationKivipelto et al 2002) with the exception of the Honolulu Asia aging Study where a cluster of vascular risk factors was considered (CitationKalmijn et al 2000). On the other hand, when cholesterol levels were considered later in life, the association with AD appeared not to be significant (CitationTan et al 2003; CitationReitz et al 2004). Furthermore, very recently, CitationMielke et al (2005), examined the association between cholesterol level and dementia in a population-based cohort of 70-year-old subjects followed over 18 years. Increasing TC levels at ages 70, 75, and 79 were associated with a reduced risk of dementia between age 79 and 88 (). The same discrepancy was found for studies investigating the relationship between cholesterol and MCI. In a the study by Solfrizzi et al (CitationSolfrizzi et al 2004b) of 2936 subjects between 65 and 84 years old followed over 3.5 years, multivariate analysis suggested that higher levels of serum TC had a trend for protective effect. Conversly, Kivipelto et al found that elevated serum TC levels (>6.5 mmol/L) in middle age increased the risk for MCI (OR = 2.1; 95% CI = 1.2–3.0) with an average follow-up of 21 years (CitationKivipelto et al 2001).

These surprising results may be explained by the timing of TC measurements in relation to age and clinical onset of dementia. Indeed, these different findings may be due to the fact that total cholesterol decreases with age (CitationPostglione et al 1989) and insufficient nutrition, and that, several years before dementia, blood pressure and BMI begin to decline, possibly as a result of the ongoing AD pathology, suggesting that the same may be true for TC (CitationPanza et al 2006). Decreased cholesterol might be an effect rather than a cause of dementia.

The few studies that have investigated the influence of ApoE genotype on the relationship between plasma lipid levels and dementia risk has given conflicting results (CitationNotolka et al 1998; CitationEvans et al 2000; CitationKivipelto et al 2002). Nevertheless, TC levels may be influenced by ApoE genotype (CitationNotolka et al 1998; CitationEvans et al 2000).

The pathophysiological mechanisms linking cholesterol metabolism to AD are still unknown (CitationWolozin 2004; CitationShobab et al 2005; CitationPanza et al 2006). Cholesterol influences the activity of the enzymes involved in the metabolism of the amyloid precursor protein and in the production of Aβ. Some in vitro studies have shown that a high cholesterol level results in reduced production of soluble amyloid precursor protein (CitationRacchi et al 1997; CitationSimons et al 1998) and that cholesterol modulates α-secretease cleavage of amyloid precursor protein production (CitationBodovitz and Klein 1996). This implicates the amyloid cascade leading to neuronal death. The mechanism by wich cholesterol affects Aβ production and metabolism is not fully understood, a change in membrane properties has been suggested (CitationShobab et al 2005). However, cholesterol could have several beneficial effects as well. Cholesterol forms an essential component of cell membranes and has a crucial role in neuronal plasticity (CitationPfrieger 2003). In addition, in vitro studies have suggested that cholesterol acts as an antioxidant and, therefore, has a protective role in dementia pathogenesis.

The relationship between cholesterol and AD is not clear and at times, is even, contradictory. Epidemiological studies have shown mixed results depending on if TC was assessed in middle age or later in life. A high cholesterol level in middle age seems to be a risk factor for AD, but this positive relationship is not seen in late life (CitationPanza et al 2006). Furthermore, pathophysiological data are also confusing. Given that the timing of exposure may be critical, more studies with long-term follow-up and serial assessments of TC are needed to clarify the causal relationship between cholesterol and dementia. Lastly, some studies have been performed to asses the link between other lipids and cognitive decline. First, the 24S-hydroxycholesterol, an oxidized metabolite of cholesterol which crosses the blood-brain-barrier, reflects brain cholesterol homeostasis more than plasma TC (CitationShobab et al 2005). During the early stages of AD, 24S-hydroxycholesterol concentrations are high in cerebro- spinal fluid and in peripherical circulation potentially reflecting increased cholesterol turnover in the brain (CitationLutjohann et al 2000; CitationPapassotiropoulos et al 2000; CitationKolsh et al 2004). However, in later stages of AD, concentrations of 24S-hydroxycholesterol fall, suggesting that there is a low rate of cholesterol transport as the disease progresses (CitationKolsh et al 2004). Thus, 24S-hydroxycholesterol might be a biochemical marker of worsening cognitive function in AD. Second, lipoprotein (a) (Lp(a)) is a LDL-like particle. High Lp(a) levels are associated with atherosclerosis (CitationMilionis et al 2000). Some studies provide evidence that higher Lp(a) level could be linked with AD (CitationMooser et al 2000; Solfrizzi et al 2002a). Nevertheless, larger clinical studies involving MCI patients and longitudinal studies of AD patients are needed to confirm the relationship between Lp(a) concentrations and dementia.

Statins are a first line treatment for hypercholesterolemia and secondary prevention of cardio-vascular disease. A large observational study in three hospitals in the US found that the prevalence of probable AD in the cohort taking statins was 60%–73% (p < 0.001) lower than in the total patient population or when compared with patients taking other medications typically used in the treatment of hypertension or cardiovascular disease (CitationWolozin et al 2000). This was confirmed by other cross-sectional studies () (CitationJick et al 2000; CitationHajjar et al 2002; CitationZamrini et al 2004; Dufouil et al 2005b). Nevertheless, all these studies were limited by an important indication bias since statins may have been prescribed less frequently in people with dementia. Conversly, the Cache County Study included 5092 elderly subjects, followed over 3 years, and found no association between statin use and subsequent onset of dementia or AD (CitationZandi et al 2005). However, in a study with longer follow-up (7 years) which included 344 elderly subjects (mean age = 74), statin use was associated with a slight reduction in cognitive decline as assessed by the Modified MMSE (CitationBernick et al 2005).

Table 5 Association between statin use and dementia or cognitive decline

On the other hand, 2 large randomized studies do not support a protective effect of statins against dementia. The PROSPER study assessing the benefits of pravastatine versus placebo in 70- to 82-year-old subjects followed over 3 years, did not find any significant effects of this lipid lowering agent on cognitive performance (CitationShepherd et al 2002). Nevertheless, this result could be explained by an insufficient length of follow-up. Furthermore, cognitive decline was assessed as a secondary endpoint in the Heart Protection Study, which included 20,536 patients, randomized to receive either 40 mg daily of simvastatin or a matching placebo. No statistical difference was found, but dementia was assessed by a phone interview, which may have been an important limitation (CitationHeart Protection Study Collaborative Group 2002).

Interstingly, a recent pilot double blinded study of 63 AD subjects compared atorvastatine versus placebo, and found a beneficial effect of the statin at 6 months as measured by the Alzheimer’s Disease Assessment Scale-cognitive Subscale (p < 0.03) and a trend towards a significant benefit at 12 months (p =0.055) (CitationSparks et al 2005). In this context longer trials testing statins on AD patients are ongoing.

All studies concerning statins and cognitive decline have a pathophysiological rationale. Statins inhibits HMG-CoA reductase, a key enzyme in the synthesis of cholesterol. Even though statins could be protective due to their cholesterol-lowering effects, and their reduction of atherosclerotic plaque formation, it has been suggested that statins could have a more specific effect. Indeed, simvastatin has been shown to reduce the levels of Aβ 42 and Aβ 40 in vitro and in the brain of guinea pigs (CitationFassbender et al 2001). Moreover statins show a broad range of functions, such antioxidant activity, immunomodulation and regulation of inflammatory processes which could prevent neuronal death.

The relationship between cholesterol and dementia varies, depending on when the cholesterol is measured over the life course. Midlife high cholesterol level appears to be a risk factor for dementia, especially AD. Statins and AD are an attractive avenue of research, considering the putative preventive or curative role of statins. Further long-term, placebo controlled trials need to be conducted.

Atrial fibrillation and cognitive decline

Recently, there has been increasing evidence that AF may contribute to the development of cognitive dysfunction. Most of the data have been provided by observational studies.

First, in the Rotterdam study of 6584 subjects, a positive association was found between AF and dementia (OR = 2.3, 95% CI = 1.4–3.7) or impaired cognitive functions (OR = 1.7, 95% CI = 1.2–2.5). The strongest association was found not for Vad but rather for AD with cerebrovascular disease (OR = 4.1, 95% CI = 1.7–9.7). An association was also present between AF and “pure” AD (OR = 1.8; 95% CI = 1.7–9.7) (CitationOtt et al 1997).

Similarly, other cross-sectional studies have shown that AF is associated with cognitive dysfunction, independent of stroke or other cardiovascular risk factors. For example, a study by Kilander et al of 952 men between 69 and 75 years old found that the 44 men with AF had poorer cognitive functions when compared to those without AF as assessed by the MMSE and the Trail making test, independent of stroke (CitationKilander et al 1998b). This was confirmed by a case-control study, which provided a complete cognitive assessment (CitationO’Connell et al 1998) and another cross-sectional study (CitationSabatini et al 2000).

Very recent longitudinal studies have assessed the link between AF and dementia. First, a community-based cohort study (CitationMiyasaka et al 2007) enroled 2837 subjects (mean age 71 ± 15 years) who were diagnosed with AF for the first time and followed them for a median timeof 4.6 years, found a high Kaplan-Meier cumulative rate of dementia: 22.5 per 1000 person-years whereas in the general population, the incidence of dementia was 6.8 per 1000 person-years (CitationEdland et al 2002).

Similarly, the impact of AF on the conversion to dementia from a normal cognitive status (n = 431) or mild cognitive impairment (MCI) (n = 180), was studied in elderly patients, followed over an average of 4 and 3 years for subjects with normal cognitive status and MCI, respectively. AF was significantly associated with conversion to dementia (HR = 4.63, 95% CI = 1.72–12.46) in the MCI group, but not in the cognitively normal group (HR = 1.10; 95% CI = 0.40–3.03) (CitationForti et al 2007).

There are multiple possible mechanisms explaining the association between AF and risk of dementia. Thromboembolic damage and cerebral hypo perfusion due to fluctuations in the cardiac output are involved (CitationSabatini et al 2000). Cerebrovascular disease is acknowledged to often coexist and overlap with AD and silent micro infarcts may markedly contribute to AD development (CitationKalaria 2002). Therefore, it is possible that the brain damage as a result of AF plays a significant role in the onset of AD because it brings neuronal function below a threshold where clinical symptoms begin to appear. Furthermore, experimental studies emphasises that ischemic insults or cerebrovascular insufficiency lead to increased expression of amyloid precursor protein which leads to the formation of classic AD neurodegenerative lesions (CitationKalaria 2000; Citationde la Torre 2006).

To conclude, there is some evidence that AF could be associated with AD. But there are not enough longitudinal studies. Anticoagulation is the gold standard for treatment of AF in order to prevent stroke. Nevertheless, the ability of anticoagulation therapy to prevent or postpone dementia in cases of AD has not been studied yet. Aspirin is sometime an alternative therapy for AF when anticoagulation can not be used. A longitudinal study (CitationNilsson et al 2003) of 702 elderly people found that those who used high doses aspirin had a significantly lower prevalence of AD than those who did not use aspirin, but Kang et al did not showed any benefit in prevention of cognitive decline for the 6377 women, included in the Women’s health study, after a 9.6 years follow-up (CitationKang et al 2007).

Smoking and cognitive decline

First, results from case-control studies have suggested that smoking could protect against AD (CitationGraves et al 1991) supporting a neuroprotective effect of the nicotine in cigarette smoke. On the other hand, smoking is a risk factor for atherosclerosis, cerebrovascular accidents and could cause vascular dementia (CitationShinton and Beevers 1989).

Recent prospective studies on cohorts without dementia suggest that smokers have a significantly increased risk of dementia, including AD (CitationOtt et al 1998; Launer et al 1999; CitationMerchant et al 1999). The results of the Honolulu-Asia Aging Study (CitationTyas et al 2003) are of particular interest because of data collected about the amount of smoking, neuropathologic data and the long follow-up period. The association between midlife smoking and late-life dementia was assessed in 3734 Japanese-American men. Adjusting for age, education, and Apo E genotype, the risk of AD in smokers increased with pack-years of smoking at both medium (OR = 2.18; 95% CI = 1.07–4.69) and heavy (OR = 2.40; 85% CI = 1.16–5.17) smoking levels. Neuropathologic data were available for 218 men and in an autopsied sub-sample, the number of neuritic plaques increased with smoking level.

The effects of smoking on global cognitive function in elderly subjects without dementia were also assessed in a multi-center cohort including 9,209 subjects, 65 years old and over, who were followed up 2.3 years (CitationOtt et al 2004). The average yearly decline in MMSE score was compared among groups, adjusting for age, sex, baseline MMSE, education, and stroke. The adjusted decline of former smokers was 0.03 points greater than subjects who never smoked. For current smokers, this decline was 0.13 point greater than subjects who never smoked (p < 0.001), suggesting that smoking may accelerate cognitive decline in elderly people without dementia.

Finally, a recent meta-analysis (CitationAnstey et al 2007), of 19 prospective studies with at least a 12-month follow-up period concluded that smokers at baseline, had risks of 1.79 (95% CI = 1.43–2.23) for incident AD, 1.78 (95% CI = 1.28–2.47) for incident Vad and 1.27 (95% CI = 1.02–1.60) for any dementia, relative to subjects who had never smoked. The authors concluded that elderly smokers have an increased risk of dementia and cognitive decline.

Smoking could affect cognition through various mechanisms. First, chronic tobacco exposure causes atherosclerosis which increase the risk of silent brain infarctions (CitationCruickshank et al 1989). Smoking may also be linked to AD by mechanisms leading to plaque formation. Smokers may experience greater oxidative stress than non-smokers and increased oxidative stress may cause neuronal degeneration (CitationMarkesbery 1997). Nevertheless, these underlying mechanisms are insufficiently understood and require further experimental studies.

Atherosclerosis, coronary artery disease, heart failure, and cognitive decline

Atherosclerosis is believed to be involved in development of dementia and its major subtypes, vascular dementia and AD (Citationde la Torre 2004). The association may be mediated by cerebrovascular disease or result from brain hypo perfusion.

Indeed, there is some epidemiologic evidence for a relation between atherosclerosis and dementia risk. According to a cross-sectional report from the Rotterdam study (CitationHofman et al 1997), a strong association was found between atherosclerosis and dementia, especially AD (OR = 3.0; 95% CI = 1.5–3.2). Furthermore, a very recent longitudinal study, including 6647 participants in the Rotterdam study with a mean follow-up of 9 years, disclosed that atherosclerosis (common carotid intima media thickness, carotid plaques, peripheral artery disease), predominantly carotid atherosclerosis, was associated with an increased risk for any type of dementia (Citationvan Oijen et al 2007). In the same way, a significant relationship between aterial stiffness and cognitive impairment has been showed (CitationHanon et al 2005a). This association has been recently confirmed in a longitudinal study (Waldstein et al 2008).

These results suggest an independent relationship between atherosclerosis and AD (CitationCasserly and Topol 2004). Indeed, the two diseases share common risks factors and pathophysiological elements. Hypercholesterolemia, oxydative stress and inflammation have emerged as the dominant mechanisms in the development of both atherosclerosis and AD (CitationSteinberg 2002). In the same way, the ε4 allele of the Apo E gene represents a genetic risk factor for atherosclerosis (CitationWilson et al 1996) and the most important genetic risk factor for sporadic AD in the general population (CitationFarrer et al 1997). Furthermore, vascular endothelial cells could play a role in the secretion of the precursor substrate of the neurotoxic A beta-protein leading to the destruction of cortical neurons in AD (CitationVagnucci and Li 2003). Likewise, endothelial lesions in AD have been related to the location and number of senile plaques (CitationKalaria and Hedera 1996) and it has been reported that beta amyloid could interact with vascular endothelial cells to produce an excess of free radicals (CitationThomas et al 1996).

Some investigations have shown the importance of inflammation in the pathogenesis of AD (CitationAkiyama et al 2000). Fibrillar Aβ has been shown to directly activate the complement pathway in vitro. Furthermore, all the cytokines and chemokines seem to be upregulated in AD. The migcroglia seems to be the most important cell mediator in the AD brain. Microglia cluster at sites of Aβ deposition and could play a role through the processing of APP and Aβ or in the conversion of nonfibrillar Aβ into amyloid fibrils.

In this way findings from observational studies have supported a treatment benefit of low dose aspirin and non steroidal anti-inflammatory drugs in AD (CitationEtminam et al 2003). However, results from a randomized study of the effects of a selective COX-2 inhibitor on disease progression have been negative (CitationReines et al 2004).

Moreover, coronary heart disease, one the major complications of atherosclerosis, has been associated with cognitive decline. In the cardiovascular health study cohort, including 3602 subjects followed up 5.4 years, the incidence of dementia was higher in those with prevalent coronary artery disease. The rate of AD was 34.4 per 1000 person-years for subjects with coronary heart disease versus 22.2 per 1000 person-years without coronary heart disease (HR = 1.3; 95% CI = 1.0–1.7) (CitationNewman et al 2005). Furthermore, a recent anatomopathological study disclosed that, coronary artery disease was associated with AD’s neuropathological hallmarks in APoE 4 carriers (CitationBeeri et al 2006).

Congestive heart failure may also be an atherosclerosis’ complication and is a common medical condition among elderly people (CitationCowie et al 1997). Some studies have assessed the link between heart failure and cognitive impairment. It has been observed a higher prevalence of heart failure in people with cognitive disorders and the risk of cognitive impairment was 1.96-fold greater in subjects with chronic heart failure (CHF) (OR = 1.96; 95% CI = 1.07–3.58)compared to those without CHF (CitationCacciatore et al 1998). These results have been confirmed in a large study including 13,635 patients showing an increased prevalence of cognitive disorders among patients with heart failure (CitationZuccala et al 2001). Particularly, low blood pressure was significantly associated with cognitive impairment in patients with heart failure (CitationZuccala et al 2001) suggesting the role of low cardiac output in cognitive dysfunction. Furthermore, in a 10-year prospective study, including 650 elderly people, cognitive decline was predicted by various vascular factors including heart failure (RR = 1.8) (CitationTilvis et al 2004).

Few studies have assessed a putative association between chronic heart failure and dementia.

A recent study addressed prospectively the relationship between heart failure and dementia among 1301 individuals 75 years or older, with cognitive evaluation 3 times over a 9-year period (CitationQiu et al 2006). Heart failure was associated with a multi-adjusted HR of 1.84 (95% CI: 1.35–2.51) for dementia and 1.80 (95% CI: 1.25–2.61) for AD. In this trial, heart failure and low diastolic blood pressure (<70 mmHG) had an additive effect on the risk for developing dementia (HR = 3.07; 95% CI: 1.64–5.61). The potential biological pathways linking heart failure to cognitive impairment, dementia and AD are still unknown. First, heart failure is a risk factor for multiple cerebral emboli which could lead to cognitive impairment (CitationPullicino and Hart 2001). Second, low cardiac output may result in decreased cerebral perfusion which could play a part in the neurodegenerative process (CitationPullicino and Hart 2001). Prospective studies, concerning the effect of cardiac heart failure treatment need to be conducted. In the study by Qiu et al it is suggested that the use of antihypertensive drugs (83% of which were diuretics) could reduce the risk of dementia related to heart failure (CitationQiu et al 2006) and ACE inhibitors have been suggested to improve cognitive performance in patients with heart failure (CitationZuccala et al 2005). Nevertheless, some long-term prospective studies have to test this hypothesis

Conclusion

Vascular risk factors may impair cognitive functions and are related to the occurrence of not only Vad but also AD. This level of evidence for these associations is highest for hypertension and DM, especially when these factors are assessed in middle age. Furthermore, a dementia risk score, including age, sex, education, SBP, TC, physical activity and ApoE ε4 genotype, was recently proposed (CitationKivipelto et al 2006), but should be validated and further refined to increase its predictive value. Considering pathophysiological mechanisms, there are mechanistic studies that provide leads, but do not indicate which of these leads are clinically relevant. Some studies have highlighted the possible protective effect of antihypertensive therapy on cognition and some trials are assessing the effects of statins and treatments for insulin-resistance. Considering that dementia is a worldwide problem, finding a preventive or curative treatment is a major health concern, and vascular risk factors are a promising avenue of research. Further long-term, placebo-controlled, randomized studies, need to be performed, eg, antihypertensive therapy, statins, glitazones, antithrombotic agents versus placebo to slow down cognitive decline in MCI or AD populations even though in the absence of hypertension, hypercholesterolemia, and diabetus mellitus.

References

  • ADVANCERationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled EvaluationJ Hypertens Suppl200119S218
  • AkomolafeABeiserAMeigsJBDiabetes mellitus and risk of developing Alzheimer disease: results from the Framingham StudyArch Neurol2006631551517101823
  • AkiyamaHBargerSBarnumSInflammation and Alzheimer’s diseaseNeurobiol Aging20002138342110858586
  • AllenKVFrierBMStrachanMWThe relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitationsEur J Pharmacol20044901697515094083
  • AnsteyKJvon SandenCSalimASmoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studiesAm J Epidemiol20071663677817573335
  • ArreguiAPerryEKRossorMAngiotensin converting enzyme in Alzheimer’s disease increased activity in caudate nucleus and cortical areasJ Neurochem198238149026278093
  • ArvanitakisZWilsonRSBieniasJLDiabetes mellitus and risk of Alzheimer disease and decline in cognitive functionArch Neurol200461661615148141
  • BeeriMSRappMSilvermanJMCoronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriersNeurology200666139940416682673
  • BellewKMPigeonJGStangPEHypertension and the rate of cognitive decline in patients with dementia of the Alzheimer typeAlzheimer Dis Assoc Disord2004182081315592132
  • BenoitSCCleggDJSeeleyRJInsulin and leptin as adiposity signalsRecent Prog Horm Res2004592678514749506
  • BernickCKatzRSmithNLCardiovascular Health Study Collaborative Research Group. Statins and cognitive function in the elderly: the Cardiovascular Health StudyNeurology20056513889416275825
  • BiesselsGJStaekenborgSBrunnerERisk of dementia in diabetes mellitus: a systematic reviewLancet Neurol20065647416361024
  • BirkenhagerWHStaessenJAProgress in cardiovascular diseases: cognitive function in essential hypertensionProg Cardiovasc Dis20064911016867845
  • BirnsJMorrisRDonaldsonNThe effects of blood pressure reduction on cognitivefunction: a review of effects based on pooled data from clinical trialsJ Hypertens20062419071416957545
  • BlackerDHainesJLRodesLApoE-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiativeNeurology199748139479008509
  • BodovitzSKleinWLCholesterol modulates alpha-secretase cleavage of amyloid precursor proteinJ Biol Chem19962714436408626795
  • BohannonADFillenbaumGGPieperCFRelationship of race/ethnicity and blood pressure to change in cognitive functionJ Am Geriatr Soc200250424911943035
  • BondyCAChengCMSignaling by insulin-like growth factor 1 in brainEur J Pharmacol2004490253115094071
  • BoschJYusufSPogueJHOPE InvestigatorsHeart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trialBMJ200232469970211909785
  • BrandsAMBiesselsGJde HaanEHThe effects of type 1 diabetes on cognitive performance: a meta-analysisDiabetes Care2005287263515735218
  • CacciatoreFAbetePFerraraNOsservatorio Geriatrico Campano Study GroupCongestive heart failure and cognitive impairment in an older populationJ Am Geriatr Soc199846134389809754
  • CasserlyITopolEConvergence of atherosclerosis and Alzheimer’s disease: inflammation, cholesterol, and misfolded proteinsLancet200436311394615064035
  • CowieMRMosterdAWoodDAThe epidemiology of heart failureEur Heart J199718208259043837
  • CruickshankJMNeil-DwyerGDorranceDEAcute effects of smoking on blood pressure and cerebral blood flowJ Hum Hypertens1989344392691689
  • CummingsJLAlzheimer’s diseaseN Engl J Med2004351566715229308
  • CurbJDRodriguezBLAbbottRDLongitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose toleranceNeurology199952971510102414
  • DavignonJGreggRESingCFApolipoprotein E polymorphism and atherosclerosisArteriosclerosis198881213277611
  • DebetteSBomboisSBruandetASubcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairmentStroke20073829243017885256
  • de la TorreJCIs Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialecticsLancet Neurol200431849014980533
  • de la TorreJCHow do heart disease and stroke become risk factors for Alzheimer’s disease?Neurol Res2006286374416945216
  • de LeeuwFERichardFde GrootJCInteraction between hypertension, apoE, and cerebral white matter lesionsStroke20043510576015060316
  • Di BariMPahorMFranseLVDementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trialAm J Epidemiol200115372811159149
  • DikMGJonkerCComijsHCContribution of metabolic syndrome components to cognition in older personsDiabetes Care20073026556017563341
  • DufouilCChalmersJCoskunOPROGRESS MRI Substudy InvestigatorsEffects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging SubstudyCirculation200511216445016145004
  • DufouilCRichardFFievetNAPOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City StudyNeurology2005641531815883313
  • EdlandSDRoccaWAPetersenRCDementia and Alzheimer disease incidence rates do not vary by sex in Rochester, MinnArch Neurol20025915899312374497
  • EichnerJEDunnSTPerveenGApolipoprotein E polymorphism and cardiovascular disease: a HuGE reviewAm J Epidemiol20021554879511882522
  • EliasMFWolfPAD’AgostinoRBUntreated blood pressure level is inversely related to cognitive functioning: the Framingham StudyAm J Epidemiol1993138353648213741
  • EtminanMGillSSamiiAEffect of non-steroidal anti – inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studiesBMJ20031912812869452
  • EvansRMEmsleyCLGaoSSerum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: a population-based study of African AmericansNeurology200054240210636159
  • Expert Panel Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in AdultsExecutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA200128524869711368702
  • FarmerMEWhiteLRAbbottRDBlood pressure and cognitive performance. The Framingham StudyAm J Epidemiol19871261103143687920
  • FarrerLACupplesLAHainesJLEffects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis ConsortiumJAMA19972781349569343467
  • FassbenderKSimonsMBergmannCSimvastatin strongly reduces levels of Alzheimer’s disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivoProc Natl Acad Sci USA20019858566111296263
  • FeiginVRatnasabapathyYAndersonCDoes blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease?J Neurol Sci2005229230151515760634
  • FerriCPPrinceMBrayneCAlzheimer’s Disease International. Global prevalence of dementia: a Delphi consensus studyLancet20053662112716360788
  • ForetteFSeuxMLStaessenJAPrevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trialLancet19983521347519802273
  • ForetteFSeuxMLStaessenJASystolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) studyArch Intern Med200216220465212374512
  • FortiPMaioliFPisacaneNAtrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment (MCI)Arch Gerontol Geriatr2007441556517317449
  • FreitagMHPeilaRMasakiKMidlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging StudyStroke20063733716339468
  • GaspariniLXuHPotential roles of insulin and IGF-1 in Alzheimer’s diseaseTrends Neurosci200326404612900169
  • GlynnRJBeckettLAHebertLECurrent and remote blood pressure and cognitive declineJAMA1999281438459952204
  • GorospeECDaveJKThe risk of dementia with increased body mass indexAge Ageing20073623917124253
  • GravesABvan DuijnCMChandraVEURODEM Risk Factors Research GroupAlcohol and tobacco consumption as risk factors for Alzheimer’s disease: a collaborative re-analysis of case-control studiesInt J Epidemiol199120S48571833354
  • GuoZViitanenMFratiglioniLLow blood pressure and dementia in elderly people: the Kungsholmen projectBMJ199631280588608286
  • GuoZFratiglioniLWinbladBBlood pressure and performance on the Mini-Mental State Examination in the very old. Cross-sectional and longitudinal data from the Kungsholmen ProjectAm J Epidemiol19971451106139199540
  • GuoZFratiglioniLZhuLOccurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication useArch Neurol199958991610448805
  • GustafsonDRothenbergEBlennowKAn 18-year follow-up of overweight and risk of Alzheimer diseaseArch Intern Med20031631524812860573
  • GustafsonDAdiposity indices and dementiaLancet Neurol200657132016857578
  • HajjarISchumpertJHirthVThe impact of the use of statins on the prevalence of dementia and the progression of cognitive impairmentJ Gerontol A Biol Sci Med Sc2002574148
  • HanonOHaulonSLenoirHRelationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory lossStroke2005a362193716151027
  • HanonOLatourFSeuxMLF; REAL.FR GroupEvolution of blood pressure in patients with Alzheimer’s disease: a one year survey of a French Cohort (REAL.FR)J Nutr Health Aging2005b91061115791354
  • HanonOPequignotRSeuxMLRelationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaintsJ Hypertens2006242101716957572
  • HardyJAMannDMWesterPAn integrative hypothesis concerning the pathogenesis and progression of Alzheimer’s diseaseNeurobiol Aging198674895022882432
  • HarrisMIDiabetes in America: epidemiology and scope of the problemDiabetes Care199821Suppl 3C1149850480
  • HassingLBJohanssonBNilssonSEDiabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest oldInt Psychogeriatr2002142394812475085
  • Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
  • HeckbertSRLongstrethWTJrPsatyBMThe association of antihypertensive agents with MRI white matter findings and with Modified Mini-Mental State Examination in older adultsJ Am Geriatr Soc1997451423339400550
  • HofmanAOttABretelerMMAtherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam StudyLancet199734915149111537
  • HsuehWGenetic discoveries as the basis of personalized therapy: rosiglitazone treatment of Alzheimer’s diseasePharmacogenomics J20066222416865098
  • JansonJLaedtkeTParisiJEIncreased risk of type 2 diabetes in Alzheimer diseaseDiabetes2004534748114747300
  • JickHZornbergGLJickSSStatins and the risk of dementiaLancet200035616273111089820
  • KalariaRNHederaPbeta-Amyloid vasoactivity in Alzheimer’s diseaseLancet1996347149238676667
  • KalariaRNThe role of cerebral ischemia in Alzheimer’s diseaseNeurobiol Aging2000213213010867217
  • KalariaRSimilarities between Alzheimer’s disease and vascular dementiaJ Neurol Sci2002203–2042934
  • KalmijnSFoleyDWhiteLMetabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging studyArterioscler Thromb Vasc Biol20002022556011031212
  • KangJHCookNMansonJLow dose aspirin and cognitive function in the women’s health study cognitive cohortBMJ200733498717468120
  • KhachaturianASZandiPPLyketsosCGAntihypertensive medication use and incident Alzheimer disease: the Cache County StudyArch Neurol2006636869216533956
  • KilanderLNymanHBobergMHypertension is related to cognitive impairment: a 20-year follow-up of 999 menHypertension1998a3178069495261
  • KilanderLAndrenBNymanHAtrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly menStroke1998b291816209731601
  • KivipeltoMHelkalaELLaaksoMPMidlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based studyBMJ200132214475111408299
  • KivipeltoMHelkalaELLaaksoMPApolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer diseaseAnn Intern Med20021371495512160362
  • KivipeltoMNganduTLaatikainenTRisk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based studyLancet Neurol200657354116914401
  • KnopmanDBolandLLMosleyTAtherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular risk factors and cognitive decline in middle-aged adultsNeurology20015642811148234
  • KölschHHeunRKerksiekAAltered levels of plasma 24S- and 27-hydroxycholesterol in demented patientsNeurosci Lett2004368303815364416
  • KumariMBrunnerEFuhrerRMinireview: mechanisms by which the metabolic syndrome and diabetes impair memoryJ Gerontol A Biol Sci Med Sci20005B2283210819309
  • KuusistoJKoivistoKMykkanenLAssociation between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: cross sectional population based studyBMJ1997315104599366728
  • KwonHMKimBJLeeSHMetabolic syndrome as an independent risk factor of silent brain infarction in healthy peopleStroke2006374667016373631
  • LaunerJMasakiKPetrovitchHThe association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging StudyJAMA19952741846517500533
  • LaunerLJRossGWPetrovitchHMidlife blood pressure and dementia: the Honolulu-Asia aging studyNeurobiol Aging200021495510794848
  • LithellHHanssonLSkoogISCOPE Study GroupThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens2003218758612714861
  • LuchsingerJATangMXSternYDiabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohortAm J Epidemiol20011546354111581097
  • LuchsingerJATangMXSheaSHyperinsulinemia and risk of Alzheimer diseaseNeurology20046311879215477536
  • LuchsingerJAReitzCHonigLSAggregation of vascular risk factors and risk of incident Alzheimer diseaseNeurology2005655455116116114
  • LuchsingerJAReitzCPatelBRelation of diabetes to mild cognitive impairmentArch Neurol200764570517420320
  • LütjohannDPapassotiropoulosABjörkhemIPlasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patientsJ Lipid Res200041195810681402
  • MacKnightCRockwoodKAwaltEDiabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and AgingDement Geriatr CognDisord2002147783
  • MarkesberyWROxidative stress hypothesis in Alzheimer’s diseaseFree Radic Biol Med199723134479165306
  • MartinsCAOulhajAde JagerCAAPOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear modelNeurology20056518889316380608
  • MasseIBordetRDeplanqueDLipid lowering agents are associated with a slower cognitive decline in Alzheimer’s diseaseJ Neurol Neurosurg Psychiatry2005761624916291883
  • MaxwellCJHoganDBEblyEMCalcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and AgingCMAJ1999161501610497605
  • McGuinnessBToddSPassmorePThe effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular diseaseCochrane Database Syst Rev20062CD00403416625595
  • MerchantCTangMXAlbertSThe influence of smoking on the risk of Alzheimer’s diseaseNeurology19995214081210227626
  • MielkeMMZandiPPSjogrenMHigh total cholesterol levels in late life associated with a reduced risk of dementiaNeurology20056416899515911792
  • MilesWRootHPsychologic tests applies to diabetic patientsArch Int Med1922307677
  • MilionisHJWinderAFMikhailidisDPLipoprotein (a) and strokeJ Clin Pathol2000534879610961170
  • MiyasakaYBarnesMEPetersenRCRisk of dementia in stroke–free patients diagnosed with atrial fibrillation: data from a community-based cohortEur Heart J2007281962717459900
  • MoroneyJTTangMXBerglundLLow-density lipoprotein cholesterol and the risk of dementia with strokeJAMA19992822546010422994
  • MorrisMCScherrPAHebertLEAssociation of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community studyArch Neurol2001581640611594923
  • MooserVHelbecqueNMiklossyJInteractions between apolipoprotein E and apolipoprotein (a) in patients with late-onset Alzheimer diseaseAnn Intern Med2000132533710744589
  • MurrayMDLaneKAGaoSPreservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African AmericansArch Intern Med20021622090612374517
  • NewmanABFitzpatrickALLopezODementia and Alzheimer’s disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohortJ Am Geriatr Soc2005531101716108925
  • NilssonSEJohanssonBTakkinenSDoes aspirin protect against Alzheimer’s dementia? A study in a Swedish population-based sample aged ≥80 yearsEur J Clin Pharmacol200359313912827329
  • NotkolaILSulkavaRPekkanenJSerum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s diseaseNeuroepidemiology19981714209549720
  • O’ConnellJEGrayCSFrenchJMAtrial fibrillation and cognitive function: case-control studyJ Neurol Neurosurg Psychiatry19986538699728958
  • OkumiyaKMatsubayashiKWadaTJ-curve relation between blood pressure and decline in cognitive function in older people living in community, JapanJ Am Geriatr Soc199745103239256863
  • OttABretelerMMde BruyneMCAtrial fibrillation and dementia in a population-based study. The Rotterdam StudyStroke199728316219040682
  • OttASlooterAJHofmanASmoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam StudyLancet1998351184039652667
  • OttAStolkRPvan HarskampFDiabetes mellitus and the risk of dementia: The Rotterdam StudyNeurology19995319374210599761
  • OttAAndersenKDeweyMEEURODEM Incidence Research GroupEffect of smoking on global cognitive function in nondemented elderlyNeurology200462920415037693
  • PanzaFD’IntronoAColaciccoAMVascular risk and genetics of sporadic late-onset Alzheimer’s diseaseJ Neural Transm2004111698914714217
  • PanzaFD’IntronoAColaciccoAMLipid metabolism in cognitive decline and dementiaBrain Res Rev2006512759216410024
  • PapassotiropoulosALütjohannDBagliMPlasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer’s diseaseNeuroreport20001119596210884051
  • PeilaRRodriguezBLLaunerLJHonolulu-Asia Aging StudyType 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging StudyDiabetes20025112566211916953
  • PeilaRWhiteLRMasakiKReducing the risk of dementia: efficacy of long-term treatment of hypertensionStroke20063711657016601212
  • PerlmutterLSBarronESaperiaDAssociation between vascular basement membrane components and the lesions of Alzheimer’s diseaseJ Neurosci Res199030673811787541
  • PfriegerFWCholesterol homeostasis and function in neurons of the central nervous systemCell Mol Life Sci20036011587112861382
  • PiguetOGraysonDACreaseyHVascular risk factors, cognition and dementia incidence over 6 years in the Sydney Older Persons StudyNeuroepidemiology2003221657112711848
  • PostiglioneACorteseCFischettiAPlasma lipids and geriatric assessment in a very aged population of south ItalyAtherosclerosis1989806382604758
  • PrinceMJBirdASBlizardRAIs the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s trial of hypertension in older adultsBMJ199631280158608285
  • PrinsNDvan DijkEJden HeijerTCerebral white matter lesions and the risk of dementiaArchNeurol20046115314
  • PullicinoPMHartJCognitive impairment in congestive heart failure?: Embolism vs hypoperfusionNeurology2001571945611739807
  • QiuCWinbladBViitanenMPulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal studyStroke200334594912624277
  • QiuCWinbladBMarengoniAHeart failure and risk of dementia and Alzheimer disease: a population-based cohort studyArch Intern Med20061661003816682574
  • QiuWQFolsteinMFInsulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesisNeurobiol Aging200627190816399206
  • RacchiMBaettaRSalviettiNSecretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol contentBiochem J199732289389148766
  • RazayGVreugdenhilAWilcockGThe metabolic syndrome and Alzheimer diseaseArch Neurol20076493617210814
  • ReaTDBreitnerJCPsatyBMStatin use and the risk of incident dementia: the Cardiovascular Health StudyArch Neurol20056210475116009757
  • ReinesSABlockGAMorrisJCRofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled studyNeurology200462667114718699
  • ReinprechtFElmstahlSJanzonLHypertension and changes of cognitive function in 81-year-old men: a 13-year follow-up of the population study “Men born in 1914”, SwedenJ Hypertens200321576612544436
  • ReitzCTangMXLuchsingerJRelation of plasma lipids to Alzheimer disease and vascular dementiaArch Neurol2004617051415148148
  • RennieKLJebbSAPrevalence of obesity in Great BritainObes Rev2005611215655034
  • RomasSNTangMXBerglundLAPOE genotype, plasma lipids, lipoproteins, and AD in community elderlyNeurology1999535172110449113
  • RosengrenASkoogIGustafsonDBody mass index, other cardiovascular risk factors, and hospitalization for dementiaArch Intern Med2005165321615710796
  • SabatiniTFrisoniGBBarbisoniPAtrial fibrillation and cognitive disorders in older peopleJ Am Geriatr Soc2000483879010798464
  • SaundersAMStrittmatterWJSchmechelDAssociation of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s diseaseNeurology1993431467728350998
  • ScherrPAHebertLESmithLARelation of blood pressure to cognitive function in the elderlyAm J Epidemiol19911341303151755444
  • Schnaider BeeriMGoldbourtUSilvermanJMDiabetes mellitus in midlife and the risk of dementia three decades laterNeurology2004631902715557509
  • SeuxMLThijsLForetteFCorrelates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia ProjectJ Hypertens19981696399794736
  • SHEP Cooperative Research GroupPrevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)JAMA19912653255642046107
  • ShepherdJBlauwGJMurphyMBPROSPER study groupPROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet200236016233012457784
  • ShintonRBeeversGMeta-analysis of relation between cigarette smoking and strokeBMJ1989298789942496858
  • ShobabLAHsiungGYFeldmanHHCholesterol in Alzheimer’s diseaseLancet Neurol200548415216297842
  • SimonsMKellerPDe StrooperBCholesterol depletion inhibits the generation of beta-amyloid in hippocampal neuronsProc Natl Acad Sci USA199895646049600988
  • SkoogILernfeltBLandahlS15-year longitudinal study of blood pressure and dementiaLancet1996347114158609748
  • SkoogILithellHHanssonLSCOPE Study GroupEffect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE)Am J Hypertens2005181052916109319
  • SnowdonDAGreinerLHMortimerJABrain infarction and the clinical expression of Alzheimer disease. The Nun StudyJAMA199727781379052711
  • SolfrizziVPanzaFD’IntronoALipoprotein (a), apolipoprotein E genotype, and risk of Alzheimer’s diseaseJ Neurol Neurosurg Psychiatry200272732612023414
  • SolfrizziVPanzaFColaciccoAMItalian Longitudinal Study on Aging Working GroupVascular risk factors, incidence of MCI, and rates of progression to dementiaNeurology20046318829115557506
  • SparksDLScheffSWHunsakerJCInduction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterolExp Neurol199412688948157129
  • SparksDLSabbaghMNConnorDJAtorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary resultsArch Neurol200562753715883262
  • StarrJMWhalleyLJInchSBlood pressure and cognitive function in healthy old peopleJ Am Geriatr Soc19934175368315187
  • StarrJMWhalleyLJDearyIJThe effects of antihypertensive treatment on cognitive function: results from the HOPE studyJ Am Geriatr Soc19964441158636587
  • StarrJMDearyIJInchSBlood pressure and cognitive decline in healthy old peopleJ Hum Hypertens199711777819468003
  • SteinbergDAtherogenesis in perspective: hypercholesterolemia and inflammation as partners in crimeNat Med200281211712411947
  • StegmayerBAsplundKDiabetes as a risk factor for stroke. A population perspectiveDiabetologia199538106188591820
  • SwanGECarmelliDLarueASystolic blood pressure tracking over 25 to 30 years and cognitive performance in older adultsStroke1998a292334409804644
  • SwanGEDeCarliCMillerBLAssociation of midlife blood pressure to late-life cognitive decline and brain morphologyNeurology1998b51986939781518
  • TanZSSeshadriSBeiserAPlasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham StudyArch Intern Med20031631053712742802
  • ThomasTThomasGMcLendonCbeta-Amyloid-mediated vasoactivity and vascular endothelial damageNature1996380168718600393
  • TilvisRSKähönen-VäreMHJolkkonenJPredictors of cognitive decline and mortality of aged people over a 10-year periodJ Gerontol A Biol Sci Med Sci2004592687415031312
  • TyasSLWhiteLRPetrovitchHMid-life smoking and late-life dementia: the Honolulu-Asia Aging StudyNeurobiol Aging2003245899612714116
  • TzourioCDufouilCDucimetierePCognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular AgingNeurology19995319485210599763
  • TzourioCAndersonCChapmanNPROGRESS Collaborative GroupEffects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular diseaseArch Intern Med200316310697512742805
  • VagnucciAHJrLiWWAlzheimer’s disease and angiogenesisLancet2003361605812598159
  • VanhanenMKoivistoKMoilanenLAssociation of metabolic syndrome with Alzheimer disease: a population-based studyNeurology200667843716966548
  • van OijenMde JongFJWittemanJCAtherosclerosis and risk for dementiaAnn Neurol2007614031017328068
  • VergheseJLiptonRBHallCBLow blood pressure and the risk of dementia in very old individualsNeurology20036116677214694027
  • VictoroffJMackWJLynessSAMulticenter clinicopathological correlation in dementiaAm J Psychiatry19951521476847573587
  • WaldsteinSRRiceSCThayerJFPulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of AgingHypertension20071119
  • WangSYWeight loss and metabolic changes in dementiaJ Nutr Health Aging20026201511887245
  • WhiteHPieperCSchmaderKWeight change in Alzheimer’s diseaseJ Am Geriatr Soc199644265728600194
  • WhitehousePJSciulliCGMasonRMDementia drug development: use of information systems to harmonize global drug developmentPsychopharmacol Bull199733129339133764
  • WhitmerRASidneySSelbyJMidlife cardiovascular risk factors and risk of dementia in late lifeNeurology2005642778115668425
  • WhitmerRAGundersonEPBarrett-ConnorEObesity in middle age and future risk of dementia: a 27 year longitudinal population based studyBMJ2005330136015863436
  • WhitmerRAThe epidemiology of adiposity and dementiaCurr Alzheimer Res200741172217430233
  • WilsonPWSchaeferEJLarsonMGApolipoprotein E alleles and risk of coronary disease. A meta-analysisArterioscler Thromb Vasc Biol199616125058857921
  • WolozinBKellmanWRuosseauPDecreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitorsArch Neurol20005714394311030795
  • WolozinBCholesterol, statins and dementiaCurr Opin Lipidol2004156677215529026
  • XuWLQiuCXWahlinADiabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up studyNeurology2004631181615477535
  • XuWQiuCWinbladBThe effect of borderline diabetes on the risk of dementia and Alzheimer’s diseaseDiabetes200756211617192484
  • YaffeKKanayaALindquistKThe metabolic syndrome, inflammation, and risk of cognitive declineJAMA200429222374215536110
  • YaffeKBlackwellTWhitmerRAGlycosylated hemoglobin level and development of mild cognitive impairment or dementia in older womenJ Nutr Health Aging200610293516886099
  • YaffeKMetabolic Syndrome and Cognitive Disorders: Is the Sum Greater Than Its Parts?Alzheimer Dis Assoc Disord2007211677117545744
  • YaffeKHaanMBlackwellTMetabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging studyJ Am Geriatr Soc2007557586217493197
  • YamadaMKasagiFSasakiHAssociation between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health StudyJ Am Geriatr Soc200351410412588587
  • YanagisawaKCholesterol and pathological processes in Alzheimer’s diseaseJ Neurosci Res200270361612391598
  • YoshitakeTKiyoharaYKatoIIncidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama StudyNeurology199545116187783883
  • YoungSEMainousAGCarnemollaMHyperinsulinemia and cognitive decline in a middle-aged cohortDiabetes Care20062926889317130206
  • ZamriniEMcGwinGRosemanJMAssociation between statin use and Alzheimer’s diseaseNeuroepidemiology20042394814739574
  • ZandiPPSparksDLKhachaturianASCache County Study investigatorsDo statins reduce risk of incident dementia and Alzheimer disease? The Cache County StudyArch Gen Psychiatry2005622172415699299
  • ZhuLViitanenMGuoZBlood pressure reduction, cardiovascular diseases, and cognitive decline in the mini-mental state examination in a community population of normal very old people: a three-year follow-upJ Clin Epidemiol199851385919619965
  • ZuccalàGOnderGPedoneCHypotension and cognitive impairment: Selective association in patients with heart failureNeurology20015719869211739814
  • ZuccalàGOnderGMarzettiEUse of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failureEur Heart J2005262263315618043